Protara Therapeutics Past Earnings Performance
Past criteria checks 0/6
Protara Therapeutics's earnings have been declining at an average annual rate of -20.1%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-20.1%
Earnings growth rate
-0.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -51.4% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
Nov 22
Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?
Aug 08Protara: A Bombed Out Biotech With A Very Positive Skew
Feb 22Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
Dec 16We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth
Apr 22The Prognosis For Protara Therapeutics
Oct 13Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
Sep 12Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?
Mar 21Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?
Dec 06Revenue & Expenses Breakdown
How Protara Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -42 | 17 | 29 |
| 30 Jun 24 | 0 | -41 | 18 | 27 |
| 31 Mar 24 | 0 | -42 | 18 | 28 |
| 31 Dec 23 | 0 | -40 | 19 | 25 |
| 30 Sep 23 | 0 | -69 | 19 | 24 |
| 30 Jun 23 | 0 | -67 | 19 | 21 |
| 31 Mar 23 | 0 | -64 | 20 | 17 |
| 31 Dec 22 | 0 | -66 | 21 | 17 |
| 30 Sep 22 | 0 | -37 | 22 | 16 |
| 30 Jun 22 | 0 | -40 | 24 | 17 |
| 31 Mar 22 | 0 | -45 | 25 | 19 |
| 31 Dec 21 | 0 | -47 | 26 | 21 |
| 30 Sep 21 | 0 | -46 | 25 | 21 |
| 30 Jun 21 | 0 | -43 | 24 | 19 |
| 31 Mar 21 | 0 | -37 | 22 | 16 |
| 31 Dec 20 | 0 | -34 | 22 | 12 |
| 30 Sep 20 | 0 | -28 | 19 | 9 |
| 30 Jun 20 | 0 | -22 | 15 | 7 |
| 31 Mar 20 | 0 | -16 | 11 | 6 |
| 31 Dec 19 | 0 | -8 | 4 | 4 |
| 30 Sep 19 | 0 | -7 | 2 | 4 |
| 31 Dec 18 | 0 | -4 | 1 | 3 |
Quality Earnings: TARA is currently unprofitable.
Growing Profit Margin: TARA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TARA is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.
Accelerating Growth: Unable to compare TARA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TARA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: TARA has a negative Return on Equity (-51.41%), as it is currently unprofitable.